Neal Shore et al.
BJU international, 109(2), 226-232 (2011-08-20)
To evaluate the efficacy and tolerability of a once-yearly histrelin implant during an open-label extension of a pivotal study. Men with advanced prostate cancer and a clinical response to 52 weeks of treatment with the histrelin implant. Implants were placed